(63) demonstrated that patients with IKZF1 deletions were likely to benefit from allogeneic HSCT (allo-HSCT) in terms of EFS (HR 0.42, 95% CI: 0.18–1.07, P = 0.025) and OS (HR 0.35, 95% CI: 0.16–0.75, P = 0.007), compared with non-IKZF1 alteration groups in adult Ph− B-ALL populations. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.